BioCardia said today that Opko Health (NYSE:OPK) agreed to pick up a “significant” stake in its business after a merger with Tiger X Medical (OTC:CDOM). The new company will keep the BioCardia name and the development program for its CardiAMP cell therapy for heart failure patient’s who’ve had a heart attack. Stem cells derived from the bone marrow of […]
Topera said a new backer, New Enterprise Assoc., led a $25 million Series C round first reported by MassDevice.com last month, with an unnamed "strategic industry partner" joining the round.
Italian medical device maker Sorin Group (BIT:SRN) invested in early-stage company Enopace Biomedical to fund the development of a neuromodulation system for patients with congestive heart failure.
Enopace’s technology consists of an implantable neurostimulator that increases heart efficiency by reducing the workload placed on the left ventricle. Sorin Group’s $7 million investment will finance clinical studies and ongoing product development.
Semprus BioSciences Corp. won a $1 million grant to develop orthopedic devices resistant to biofilm formation for the U.S. Army’s Telemedicine & Advanced Technology Research Center.
Biofilms are the foundation for the most bacterial complications associated with implanted medical devices, according to a Semprus press release.
After a firm rejection of its buyout offer, Alere Inc. (NYSE:ALR) has started pleading to the sensibilities of Scottish competitor Axis-Sheild’s shareholders. This is not the first time the two firms have traded statements since Alere first offered its buyout in June.
Proposed Acquisition of the OCT and ultrasound business and assets of OPKO Health, Inc.
Back to press releases
22 September 2011 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, announces that it has entered into a conditional agreement with OPKO Health, Inc., OPKO Instrumentation, LLC, Ophthalmic Technologies Inc. and OTI (UK) Limited to acquire the assets and business of the instrumentation division of OPKO. OPKO Instrumentation is engaged in the development, manufacture and sale of optical coherence tomography (“OCT”) diagnostic devices and optical ultrasound scanners, each used by the ophthalmic and optometric professions in the diagnosis and management of eye disease and conditions.
Optos plc (LON:OPTS) agreed to pay $17.5 million plus royalties for Opko Health Inc.’s (NYSE:OPK) ophthalmic instruments operation.
Miami-based Opko Health said the deal is for its “worldwide activities for the development and commercialization of ophthalmic diagnostic imaging systems,” according to a press release. The plan is to integrate Opko’s OCT SLO device into Optos’ widefield technology, according to the release.